Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $365K | $571K | $134K | $0.00 | $181K | $42.0K |
| Revenue growth | — | 56.4% | -76.5% | -100.0% | — | -76.8% |
| Gross profit | $65.0K | $198K | $33.0K | $0.00 | $9.00K | $0.00 |
| Gross margin | 17.8% | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating income | -$11.2M | -$12.2M | -$13.0M | -$8.89M | -$9.59M | -$11.5M |
| Operating margin | -3059.7% | -2139.6% | -9714.2% | — | -5295.6% | -27450.0% |
| Net income | -$11.2M | -$12.2M | -$13.1M | -$8.89M | -$9.54M | -$11.4M |
| Net margin | -3072.9% | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (diluted) | $0.67 | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.6M | -$9.06M | -$12.5M | -$7.31M | -$6.82M | -$7.37M |
| Capital expenditures | $53.0K | $17.0K | $47.0K | $17.0K | $3.00K | $107K |
| Free cash flow | -$10.6M | -$9.08M | -$12.5M | -$7.33M | -$6.82M | -$7.48M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.59M | $24.9M | $12.3M | $11.0M | $8.66M | $7.11M |
| Total assets | $9.72M | $26.0M | $13.1M | $11.8M | $9.39M | $16.0M |
| Total liabilities | $2.21M | $3.42M | $1.37M | $1.38M | $1.31M | $2.89M |
| Shareholders' equity | $7.51M | $22.6M | $11.8M | $10.4M | $8.08M | $13.1M |
| Retained earnings | -$70.2M | -$82.4M | -$95.5M | -$104M | -$114M | -$125M |
| Shares (wtd avg diluted) | 21.1M | 26.1M | 28.8M | 29.0M | 37.7M | 46.2M |
Every figure is extracted from Entera Bio Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.